Figures & data
Table 1 Expression Patterns and Prognostic Value of miR-335 in Multiple Types of Human Cancer
Table 2 MiR-335 Regulates Cell Proliferation and Apoptosis in Various Cancer Types
Figure 1 MiR-335 regulates cell migration and invasion in cancers through regulating various targets. By targeting RANKL, IGF-IR, ROCK1, BCL-W, Survivin, SHH, LDHB, C-Met, SIX2, OCT4, CPNE1, ICAM-1 and CRKL, miR-186 suppresses cell migration and invasion in cancers.
![Figure 1 MiR-335 regulates cell migration and invasion in cancers through regulating various targets. By targeting RANKL, IGF-IR, ROCK1, BCL-W, Survivin, SHH, LDHB, C-Met, SIX2, OCT4, CPNE1, ICAM-1 and CRKL, miR-186 suppresses cell migration and invasion in cancers.](/cms/asset/3cd5b457-482f-4dba-a91d-692a9283e966/dott_a_12176044_f0001_c.jpg)
Figure 2 MiR-335 regulates cell cycle progression in cancers through regulating various targets. MiR-335 inhibits cell cycle progression via targeting CUL4B, MEF2D, CPNE1 and ROCK1. In contrary, miR-335 promotes cell cycle progression by targeting RASA1.
![Figure 2 MiR-335 regulates cell cycle progression in cancers through regulating various targets. MiR-335 inhibits cell cycle progression via targeting CUL4B, MEF2D, CPNE1 and ROCK1. In contrary, miR-335 promotes cell cycle progression by targeting RASA1.](/cms/asset/04ccbaca-6e15-4330-96a8-45d8009403a1/dott_a_12176044_f0002_c.jpg)
Figure 3 MiR-335 regulates the sensitivity of cancer cells to the anti-cancer treatment. MiR-335 enhances the sensitivity of cancer cells to the anti-cancer treatment via the inhibition of PARP-1, POU5F1, ROCK1, SIAH2, CCNB1, Bcl-W, WBP5, C-Met and CPNE1.
![Figure 3 MiR-335 regulates the sensitivity of cancer cells to the anti-cancer treatment. MiR-335 enhances the sensitivity of cancer cells to the anti-cancer treatment via the inhibition of PARP-1, POU5F1, ROCK1, SIAH2, CCNB1, Bcl-W, WBP5, C-Met and CPNE1.](/cms/asset/231dfa40-5896-4a20-a5e0-0016f2e32af7/dott_a_12176044_f0003_c.jpg)
Figure 4 MiR335-related signaling pathways.1, Hedgehog signalling pathway: miR335 inhibites cell growth, and metastasis and drug sensitivity via suppressing Hedgehog pathway. 2, PI3K/AKT/mTOR signaling pathway: miR-335 inhibites cell growth, and metastasis drug sensitivity through suppressing AKT/mTOR signaling pathway. 3. Hippo/YAP signalling pathway: miR335 regulate drug sensitivity and apoptosis through the Hippo pathway.
![Figure 4 MiR335-related signaling pathways.1, Hedgehog signalling pathway: miR335 inhibites cell growth, and metastasis and drug sensitivity via suppressing Hedgehog pathway. 2, PI3K/AKT/mTOR signaling pathway: miR-335 inhibites cell growth, and metastasis drug sensitivity through suppressing AKT/mTOR signaling pathway. 3. Hippo/YAP signalling pathway: miR335 regulate drug sensitivity and apoptosis through the Hippo pathway.](/cms/asset/4ee43a28-bbb8-4438-ae3c-637baaa3ae64/dott_a_12176044_f0004_c.jpg)
Table 3 Regulatory Factors Suppress the Expression of miR-335 in Human Cancer